The novel drug P2B001 is superior to its individual components of pramipexole or rasagiline for early Parkinson s disease ― with less daytime sleepiness, new topline results suggest.
A phase 3 study evaluating a novel fixed-dose combination of extended release pramipexole and rasagiline (P2B001) in adults with early Parkinson disease met its primary and key secondary endpoints.
Israeli Parkinson s treatment shows positive results, eyes FDA approval jpost.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from jpost.com Daily Mail and Mail on Sunday newspapers.
Pharma Two B, a company that uses reformulations and combinations of previously approved drugs to develop new therapies for neurological indications, announced its novel therapy for Parkinson’s disease met primary and secondary endpoints. The drug, P2B001, combines extended-release formulations of 0.6 mg of pramipexole and 0.75 mg of rasagiline in a fixed dose. It features both components